The content on this site is intended for healthcare professionals only
Dr Wei speaks with ecancertv at ASH 2016 about treating AML in elderly patients with venetoclax, a Bcl-2 inhibitor, and cytarabine (ara-c).
He describes patient outcomes following venetoclax 600mg and low-dose cytarabine, with high response and complete remission rates.
Dr Wei summarises subgroup analysis, and outlines how results maturing in the future will better inform any changes to practice.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Addressing the rise of multiple myeloma in Rwanda
EHA 2024: Multiple myeloma roundup
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
